Bymetric
UK company intelligence
Company Active LTD

Company profile

Adaptimmune Limited

UK company 06456741, incorporated on 19 December 2007.

Adaptimmune Therapeutics plc (ADAP)

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients

Company number
06456741
Incorporated
19 Dec 2007
Companies House status
Active

Company identity

Founded / incorporated
19 December 2007

Company number 06456741

Verify at Companies House
Legal name
ADAPTIMMUNE LIMITED
Company type
Private Limited Company
Region
South East England
Registered address
THE INNOVATION CENTRE 99 PARK DRIVE
MILTON PARK
ABINGDON
OXFORDSHIRE
ENGLAND
OX14 4RY
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Adaptimmune Limited
CRN 06456741
2
Direct and ultimate controller Active PLC
Adaptimmune Therapeutics PLC
CRN 09338148

Company events

Reference milestones and recent Companies House filing stream events.

5 events
02 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

18 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

19 Dec
2007

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2014
Funded years
2014
Age at first award
6 years

Projects

2014 Collaborative R&D Lead participant

Clinical Development of an Adoptive T cell Therapy for Triple Negative Breast Cancer

1 Jan 2014 to 31 Dec 2016

Awarded
£2,154,221
Total cost £3,604,625

Adaptimmune has developed the adoptive transfer of T cells genetically engineered to express optimised affinity T cell Receptors (TCR) that target cancer peptide antigens. This approach generates potent anti-tumour immunity. This disruptive therapy has the potential to treat late stage diseases, such as Triple Negative Breast Cancer, for which there is a ...

Product types

Collaborative R&D